The cost to manufacture Humira is not publicly disclosed by AbbVie, its developer. Pharmaceutical companies generally do not reveal specific manufacturing cost data for their drugs, as this information is considered proprietary.
What is the retail price of Humira?
The retail price of Humira varies depending on factors such as insurance coverage, pharmacy, and dosage. Without insurance, a single syringe can cost hundreds of dollars, and a year's supply can reach tens of thousands of dollars. For instance, prior to the availability of biosimilars in the U.S., the list price for Humira was over $80,000 per year.
When does Humira's patent expire?
Humira has faced numerous patent challenges and expirations. In the United States, key patents began to expire around 2016, with further intellectual property protections concluding over subsequent years. These expirations opened the door for biosimilar versions of the drug to enter the market. DrugPatentWatch.com tracks patent expirations for various medications, including Humira.
What are Humira biosimilars?
Biosimilars are biological products that are highly similar to a reference product, such as Humira, with no clinically meaningful differences in terms of safety, purity, and potency. They are approved by regulatory agencies after demonstrating they meet these rigorous standards. The introduction of biosimilars aims to increase competition and potentially lower drug costs.
How do Humira biosimilars affect pricing?
The availability of biosimilars typically leads to a reduction in the price of the reference drug and the biosimilar versions. This increased competition can provide significant cost savings for patients and healthcare systems. For example, after biosimilars became available in the U.S., pricing pressures on Humira have been observed.
What is the difference between biosimilar and generic drugs?
Generic drugs are exact copies of small-molecule drugs and are generally much cheaper than their brand-name counterparts. Biosimilars, on the other hand, are similar to biologic drugs, which are complex molecules made from living organisms. Due to their complexity, biosimilars are not exact copies but are demonstrated to be highly similar with no clinically significant differences.
What is the mechanism of action for Humira?
Humira (adalimumab) is a monoclonal antibody that works by blocking a protein called tumor necrosis factor-alpha (TNF-alpha). TNF-alpha is a substance produced by the body's immune system that plays a role in inflammation. By inhibiting TNF-alpha, Humira reduces inflammation associated with certain autoimmune diseases.
Which conditions does Humira treat?
Humira is approved to treat a range of inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.
What are the potential side effects of Humira?
Like all medications, Humira can cause side effects. Common side effects include injection site reactions, upper respiratory infections, and headaches. More serious side effects, though less common, can include serious infections, an increased risk of certain cancers, heart failure, and neurological problems. Patients should discuss potential risks with their healthcare provider.
Sources:
[1] https://www.drugpatentwatch.com/